Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
News|Articles|August 31, 2026
August 2026 in Oncology: A Look Back at FDA Approvals and Decisions
Author(s)Targeted Oncology Staff
Fact checked by: Andrea Eleazar, MHS, Ron Panarotti
August 2026 FDA oncology updates: iberdomide, zanidatamab, and daraxonrasib win approvals as fast-track designations accelerate targeted pipelines.
Advertisement
Advertisement
August 2026 saw the FDA take action across a diverse range of oncology indications, with several decisions introducing novel treatment options while a series of regulatory designations advanced promising therapies through the development pipeline. The month brought notable milestones in multiple myeloma, gastroesophageal adenocarcinoma, and metastatic pancreatic cancer, alongside growing momentum for biomarker-driven strategies in breast cancer, lung cancer, glioma, and other solid tumors.
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Advertisement
Advertisement